These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
318 related articles for article (PubMed ID: 27171110)
21. Preventive and therapeutic opportunities: targeting BAP1 and/or HMGB1 pathways to diminish the burden of mesothelioma. Carbone M; Minaai M; Takinishi Y; Pagano I; Yang H J Transl Med; 2023 Oct; 21(1):749. PubMed ID: 37880686 [TBL] [Abstract][Full Text] [Related]
22. Rat model demonstrates a high risk of tremolite but a low risk of anthophyllite for mesothelial carcinogenesis. Aierken D; Okazaki Y; Chew SH; Sakai A; Wang Y; Nagai H; Misawa N; Kohyama N; Toyokuni S Nagoya J Med Sci; 2014 Feb; 76(1-2):149-60. PubMed ID: 25130001 [TBL] [Abstract][Full Text] [Related]
23. HMGB1 released by mesothelial cells drives the development of asbestos-induced mesothelioma. Suarez JS; Novelli F; Goto K; Ehara M; Steele M; Kim JH; Zolondick AA; Xue J; Xu R; Saito M; Pastorino S; Minaai M; Takanishi Y; Emi M; Pagano I; Wakeham A; Berger T; Pass HI; Gaudino G; Mak TW; Carbone M; Yang H Proc Natl Acad Sci U S A; 2023 Sep; 120(39):e2307999120. PubMed ID: 37729199 [TBL] [Abstract][Full Text] [Related]
24. Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma. Carbone M; Yang H Clin Cancer Res; 2012 Feb; 18(3):598-604. PubMed ID: 22065079 [TBL] [Abstract][Full Text] [Related]
25. Malignant mesothelioma diagnosed at a younger age is associated with heavier asbestos exposure. Dragani TA; Colombo F; Pavlisko EN; Roggli VL Carcinogenesis; 2018 Sep; 39(9):1151-1156. PubMed ID: 29982378 [TBL] [Abstract][Full Text] [Related]
27. DNA methylation profiling of asbestos-treated MeT5A cell line reveals novel pathways implicated in asbestos response. Casalone E; Allione A; Viberti C; Pardini B; Guarrera S; Betti M; Dianzani I; Aldieri E; Matullo G Arch Toxicol; 2018 May; 92(5):1785-1795. PubMed ID: 29523930 [TBL] [Abstract][Full Text] [Related]
28. Environmental exposure to asbestos: from geology to mesothelioma. Bayram M; Bakan ND Curr Opin Pulm Med; 2014 May; 20(3):301-7. PubMed ID: 24614240 [TBL] [Abstract][Full Text] [Related]
29. Chemokine (C-C motif) ligand 3 detection in the serum of persons exposed to asbestos: A patient-based study. Xu J; Alexander DB; Iigo M; Hamano H; Takahashi S; Yokoyama T; Kato M; Usami I; Tokuyama T; Tsutsumi M; Tamura M; Oguri T; Niimi A; Hayashi Y; Yokoyama Y; Tonegawa K; Fukamachi K; Futakuchi M; Sakai Y; Suzui M; Kamijima M; Hisanaga N; Omori T; Nakae D; Hirose A; Kanno J; Tsuda H Cancer Sci; 2015 Jul; 106(7):825-32. PubMed ID: 25940505 [TBL] [Abstract][Full Text] [Related]
30. Cellular and molecular basis of the asbestos-related diseases. Rom WN; Travis WD; Brody AR Am Rev Respir Dis; 1991 Feb; 143(2):408-22. PubMed ID: 1990961 [TBL] [Abstract][Full Text] [Related]
31. Diagnostic value of microRNAs in asbestos exposure and malignant mesothelioma: systematic review and qualitative meta-analysis. Micolucci L; Akhtar MM; Olivieri F; Rippo MR; Procopio AD Oncotarget; 2016 Sep; 7(36):58606-58637. PubMed ID: 27259231 [TBL] [Abstract][Full Text] [Related]
32. Epithelial to Mesenchymal Transition in Human Mesothelial Cells Exposed to Asbestos Fibers: Role of TGF-β as Mediator of Malignant Mesothelioma Development or Metastasis via EMT Event. Turini S; Bergandi L; Gazzano E; Prato M; Aldieri E Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30609805 [TBL] [Abstract][Full Text] [Related]
33. Ultrasensitive dose-response for asbestos cancer risk implied by new inflammation-mutation model. Bogen KT Environ Res; 2023 Aug; 230():115047. PubMed ID: 36965808 [TBL] [Abstract][Full Text] [Related]
34. Malignant mesothelioma in Australia 2015: Current incidence and asbestos exposure trends. Soeberg MJ; Leigh J; van Zandwijk N J Toxicol Environ Health B Crit Rev; 2016; 19(5-6):173-189. PubMed ID: 27705544 [TBL] [Abstract][Full Text] [Related]
35. The role of genotoxicity in asbestos-induced mesothelioma: an explanation for the differences in carcinogenic potential among fiber types. Barlow CA; Lievense L; Gross S; Ronk CJ; Paustenbach DJ Inhal Toxicol; 2013 Aug; 25(9):553-67. PubMed ID: 23905972 [TBL] [Abstract][Full Text] [Related]
36. Malignant mesothelioma as an oxidative stress-induced cancer: An update. Chew SH; Toyokuni S Free Radic Biol Med; 2015 Sep; 86():166-78. PubMed ID: 25975982 [TBL] [Abstract][Full Text] [Related]
37. Mouse models for mesothelioma drug discovery and development. Seastedt KP; Pruett N; Hoang CD Expert Opin Drug Discov; 2021 Jun; 16(6):697-708. PubMed ID: 33380218 [TBL] [Abstract][Full Text] [Related]
38. Malignant mesothelioma in Lynch syndrome: A report of two cases and a review of the literature. Shih AR; Kradin RL Am J Ind Med; 2019 May; 62(5):448-452. PubMed ID: 31033031 [TBL] [Abstract][Full Text] [Related]
39. Mesotheliomas in Genetically Engineered Mice Unravel Mechanism of Mesothelial Carcinogenesis. Jean D; Jaurand MC Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30060470 [TBL] [Abstract][Full Text] [Related]
40. Malignant and non-malignant asbestos-related pleural and lung disease: 10-year follow-up study. Cvitanović S; Znaor L; Konsa T; Ivancević Z; Perić I; Erceg M; Vujović M; Vuković J; Beg-Zec Z Croat Med J; 2003 Oct; 44(5):618-25. PubMed ID: 14515425 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]